”Cybersecurity Is Patient Safety”

Avivit Kotler, Chief Information Security and Data Protection Officer at Clalit Health Services in Israel will participate in the MVA Annual Summit 2026 Novembe...

Disruptive sells former Guard platform – deal ‘not financially material’

What was formerly Guard Therapeutics became Disruptive Pharma following a reverse acquisition. Now, one of the remaining parts of the former Guard business is b...

Novo slashes Wegovy price in Sweden – “It makes sense”

Novo is cutting the price of its weight-loss drug Wegovy by 20 per cent in Sweden. According to the company, the move is not aimed at gaining market share, but ...

Mölnlycke to split into two companies

The Swedish medtech company Mölnlycke plans to separate its Operating Room Solutions (ORS) and Gloves businesses into a new stand-alone company, Mölnlycke Surgi...

Lilly is sanctioned for remarks to Swedish media

Eli Lilly is being sanctioned for statements made in an interview with a Swedish newspaper, in which a yet‑to‑be‑approved obesity drug is claimed to “stand in a...

New FDA setback for Xspray – stock plunges

The Swedish research company Xspray Pharma has received yet another negative decision from the U.S. Food and Drug Administration (FDA), linked to the company’s ...

Study finds key gut bacterium undetectable in one in three Swedish infants

One in three Swedish infants have no detectable levels of a bacterium that helps support the developing immune system, according to a new Swedish study. The fig...

Changing jobs in the Nordics? Avoid this common mistake

It is easy to assume that working in Copenhagen, Stockholm, Oslo or Helsinki will not be all that different from working in a neighbouring Nordic country. Accor...

Danish health minister: Europe must act on China

Danish politicians and medtech industry representatives are calling for closer cooperation between hospitals and companies to boost innovation. Danish Health Mi...

Orexo CEO on settlement: “Very mixed feelings”

After more than $14m in legal fees and years of uncertainty, Orexo is closing in on a settlement with the US Department of Justice.

Sanofi Sweden: ”We will work for more clinical trials”

Sanofi Sweden may represent only a modest share of the global Sanofi group, which employs nearly 80,000 people, but it still makes a significant research impact...

Hansa chair: “Too many boards spend far too much time looking inwards”

Following a change of chief executive and a sharper strategic focus, Hansa Biopharma is entering a decisive phase in the US market. As the company prepares for ...

The vaccine has saved 94 million lives – but measles is spreading again

A disease we once believed belonged to the past is now resurging in both Europe and the United States. In Sweden, 24 cases of the disease have so far been repor...

From space to the world’s first fertility app: “Physics had always been my only dream”

She was user number one. Today, more than six million women worldwide have used the fertility app Natural Cycles, which is now rapidly expanding its offering. B...

Disappointment for Diamyd in Phase III – the share price plunges

Diamyd Medical’s share was sharply down on Monday following negative Phase III results. “This outcome is highly unexpected,” said the company’s CEO, Ulf Hannelius.

Obesity dominates as future blockbusters are identified

Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.

JMP Statistical Discovery

Lost in the recruitment process? How hiring really works today

As recruitment becomes increasingly automated, candidates are expected to adapt to both human and algorithmic decision-making. Career coach Tina Persson outline...

FDA launches investigation into gene therapy following child death

The U.S. Food and Drug Administration (FDA) has initiated a safety investigation into Takeda’s Adzynma after reports that a child has died during treatment. The...

Charged with illegal pharmaceutical sales – alleged earnings of 23 million

For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...

Heart Monitoring in Breast Cancer – Essential or Excessive?

Trastuzumab and related drugs have transformed breast cancer treatment and dramatically improved survival rates. But the close cardiac monitoring required durin...

How the Nobel discovery is used in drug development

Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how t...

“There’s no magic wand” – The urgent need for new treatments

One in ten women with recurrent yeast infections develops a stubborn, hard-to-treat condition for which no effective therapies currently exist. At Danderyd Hosp...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).